The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 59 | 22.2x | 20.8x | Around median | |
Growth | 38 | 5.3% | 6.1% | Bottom tier | |
Quality | 64 | 6.8% | 6.6% | Around median | |
Safety | 65 | 2.8x | 0.7x | Around median | |
Capital Return | 76 | 3.41% | 2.02% | Top tier | |
Momentum | 27 | -6.7% | 4.1% | Bottom tier | |
Sentiment | 58 | 17 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Medtronic plc (MDT) is a global medical-device technology company operating through a broad portfolio that includes Cardiovascular, Neuroscience, Medical Surgical, and Diabetes before the completion of the MiniMed separation. The company generates revenue from selling devices, systems, catheters, consumable products, and services linked to recurring medical procedures, such as Cardiac Ablation Solutions for treating heart rhythm disorders, Cardiac Rhythm Management products such as Micra, OmniaSecure, and EV-ICD, surgical systems such as Hugo and Touch Surgery, neuroscience and spine platforms such as Stealth AXiS and AiBLE, in addition to technologies such as Symplicity Spyral and Altaviva. In the fourth quarter of fiscal 2026, management confirmed that performance was driven by the expansion of high-velocity growth platforms, with continued contribution from larger core businesses such as CRM, CST, and Surgical.
In the fourth quarter of fiscal 2026 ended April 24, 2026, Medtronic reported revenue of 9.8 billion dollars, up 9.9% on a reported basis and 6.6% organically, while adjusted EPS was 1.55 dollars. The adjusted gross margin was 65.4%, up 30 basis points year over year and 50 basis points sequentially, and the adjusted operating margin was 25.5% with adjusted operating profit of 2.5 billion dollars. For fiscal 2026, revenue was 36.4 billion dollars, up 8.4% reported and 5.8% organically, and adjusted EPS was 5.53 dollars, which management described as the strongest revenue performance in 10 years.
The latest performance mix reflects clear divergence among platforms; Cardiovascular grew 10% in the fourth quarter, driven by CAS growth of 78% globally and 124% in the United States, while Neuroscience grew 3% and Medical Surgical grew 5%, and Diabetes delivered reported growth of 15% or 8.1% organically before the MiniMed separation. From the latest available EDGAR data before the fourth quarter, the company recorded in 2026 Q3 revenue of 9.0 billion dollars, gross profit of 5.8 billion dollars, net income of 1.1 billion dollars, and EPS of 0.89, while 2026 TTM revenue was about 34.8 billion dollars and net income was 4.9 billion dollars with EPS of 3.7619.
The analyst consensus on MDT is Buy, and the average price target is 95.8 dollars, with the highest target at 119 dollars and the lowest target at 80 dollars; therefore, valuation should be read against the live price shown outside this text to determine whether the stock trades below or above the target. The P/E multiple is not available in the provided data, but the 52-week range between 73.31 and 106.33 dollars shows that the stock's valuation is moving within a relatively wide range while the market tries to balance accelerating organic growth with tariff and inflation pressures and the MiniMed separation.
Figures in the text are as of 2026-07-04; the live price is shown at the top of the page.
Medtronic announced on June 3, 2026 fourth-quarter revenue of 9.8 billion dollars, up 9.9% reported and 6.6% organic. Adjusted EPS was 1.55 dollars, while the adjusted gross margin was 65.4% and the adjusted operating margin was 25.5%. For fiscal 2026, revenue reached 36.4 billion dollars and adjusted EPS was 5.53 dollars, the strongest annual revenue performance in 10 years according to management.
The CAS business grew 78% globally in the fourth quarter, including growth of 124% in the United States, and the company added 8 points of U.S. share according to management commentary. The PFA business also grew 145% globally, and the installed Affera base in the United States increased 40% sequentially. Management said the business has moved toward an annual revenue run rate exceeding 2 billion dollars, and that it expects to reach 2 billion dollars as trailing revenue in the first quarter of fiscal 2027.
Management said Hugo procedure volume globally is growing at two to three times the market, and that the system began contributing to the Surgical business during the fourth quarter of 2026. The company launched Hugo in the United States for urology uses, and said it placed systems with leading institutions and treated the first cases there. In late April 2026, Medtronic submitted FDA 510(k) applications for General Surgery and Gynecologic indications in addition to LigaSure RAS, and the Touch Surgery platform exceeded more than 1,400 global installations with sequential growth of more than 30%.
Automated analysis for informational purposes only — not investment advice.
News during June 2026 said Medtronic acquired Scientia Vascular for 550 million dollars to strengthen stroke and vascular-care solutions. Management explained that Scientia will expand the neurovascular platform through differentiated guidewire technologies for stroke procedures, allowing every neurovascular procedure to start with Medtronic, in its words. The deal comes within an investment wave that included CathWorks, SPR Therapeutics, Beluga Medical, and CardioACC, and the company expects recent deals to add about 150 million dollars of inorganic revenue in fiscal 2027.
Medtronic expects fiscal 2027 organic revenue growth between 6.75% and 7.25% and EPS between 5.90 and 6.00 dollars, but this guidance includes several pressures. Management estimated the tariff impact on cost of goods sold at about 250 million dollars, including 75 million dollars in the first quarter, with an approximate gross-margin decline of 20 basis points when including tariffs. The company also included dilution of about 2% from mergers and acquisitions, and a headwind of roughly one point from higher fuel and transportation costs due to the conflict in the Middle East.
Medtronic completed the MiniMed IPO in early March 2026, but it still includes the Diabetes business in fiscal 2027 guidance because it remains the largest contributor during the separation process. In the fourth quarter, the Diabetes business delivered reported growth of 15% or 8.1% organically, supported by international execution, CGM momentum in the United States, and new patient starts before the commercial launch of MiniMed Flex in the summer. Geoff Martha explained that the reason for the separation is not a lack of confidence in MiniMed, but the desire to focus capital and management on Medtronic's faster-growing platforms such as CAS, Ardian, Hugo, Altaviva, and Stealth AXiS.